{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:04:56Z","timestamp":1784109896758,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"DOI":"10.7759\/cureus.112694","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:13:50Z","timestamp":1784106830000},"source":"Crossref","is-referenced-by-count":0,"title":["Maximizing Metabolic Synergy: A Review of Dual Incretin Therapy as a Step-Up Strategy Following Glucagon-Like Peptide-1 (GLP-1) Monotherapy Failure or Optimization"],"prefix":"10.7759","author":[{"given":"Soroush","family":"Ansari Lari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya S","family":"Zumot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar A","family":"Alrashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in Diabetes\u20142026","volume":"49","author":"Bajaj M","year":"2026","unstructured":"Bajaj M, McCoy RG, Balapattabi K, et al.. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes\u20142026. Diabetes Care. 2026, 49:S183-215. 10.2337\/dc26-S009","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Phelps NH","year":"2024","unstructured":"Phelps NH, Singleton RK, Zhou B, et al.. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024, 403:1027-50. 10.1016\/S0140-6736(23)02750-2","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.838410","article-title":"Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes","volume":"13","author":"Tan Q","year":"2022","unstructured":"Tan Q, Akindehin SE, Orsso CE, Waldner RC, DiMarchi RD, M\u00fcller TD, Haqq AM. Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes. Front Endocrinol (Lausanne). 2022, 13:838410. 10.3389\/fendo.2022.838410","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min JS","year":"2025","unstructured":"Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, Bae SK. A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist. Drug Des Devel Ther. 2025, 19:3509-37. 10.2147\/DDDT.S506957","journal-title":"Drug Des Devel Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352:837-53. 10.1016\/S0140-6736(98)07019-6","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01566-x","article-title":"Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes","volume":"15","author":"Gutgesell RM","year":"2024","unstructured":"Gutgesell RM, Nogueiras R, Tsch\u00f6p MH, M\u00fcller TD. Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes. Diabetes Ther. 2024, 15:1069-84. 10.1007\/s13300-024-01566-x","journal-title":"Diabetes Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"(SURPASS-1 investigators): efficacy and safety of a novel dual GIP and GLP-1 receptor agonist, tirzepatide, in patients with type 2 diabetes (SURPASS- 1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock J","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al.. (SURPASS-1 investigators): efficacy and safety of a novel dual GIP and GLP-1 receptor agonist, tirzepatide, in patients with type 2 diabetes (SURPASS- 1): a double-blind, randomised, phase 3 trial. Lancet. 2021, 398:143-55. 10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS- 3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik B","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al.. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS- 3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021, 398:583-98. 10.1016\/S0140-6736(21)01443-4","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the surpass-5 randomized clinical trial","volume":"327","author":"Dahl D","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodr\u00edguez \u00c1. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the surpass-5 randomized clinical trial. J Am Med Assoc. 2022, 327:534-45. 10.1001\/jama.2022.0078","journal-title":"J Am Med Assoc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the surpass-6 randomized clinical trial","volume":"330","author":"Rosenstock J","year":"2023","unstructured":"Rosenstock J, Fr\u00edas JP, Rodbard HW, et al.. Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the surpass-6 randomized clinical trial. J Am Med Assoc. 2023, 330:1631-40. 10.1001\/jama.2023.20294","journal-title":"J Am Med Assoc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"(SURMOUNT-2 Investigators): tirzepatide once weekly for weight management in adults with type 2 diabetes (SURMOUNT- 2): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey WT","year":"2023","unstructured":"Garvey WT, Fr\u00edas JP, Jastreboff AM, et al.. (SURMOUNT-2 Investigators): tirzepatide once weekly for weight management in adults with type 2 diabetes (SURMOUNT- 2): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2023, 402:613-26. 10.1016\/S0140-6736(23)01200-X","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden TA","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, et al.. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023, 29:2909-18. 10.1038\/s41591-023-02597-w","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne LJ","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. J Am Med Assoc. 2024, 331:38-48. 10.1001\/jama.2023.24945","journal-title":"J Am Med Assoc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"4","author":"Del Prato S","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al.. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. J Am Med Assoc. 2021, 4:1811-24. 10.1016\/S0140-6736(21)02188-7","journal-title":"J Am Med Assoc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls SJ","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL, et al.. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025, 393:2409-20. 10.1056\/NEJMoa2505928","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2026.0767","article-title":"Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease: a post hoc analysis of the surpass-CVOT randomized clinical trial","volume":"11","author":"Nissen SE","year":"2026","unstructured":"Nissen SE, Wolski K, D'Alessio D, et al.. Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease: a post hoc analysis of the surpass-CVOT randomized clinical trial. JAMA Cardiol. 2026, 11:544-52. 10.1001\/jamacardio.2026.0767","journal-title":"JAMA Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025, 392:427-37. 10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04440-4","article-title":"Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial","author":"Pratley RE","year":"2026","unstructured":"Pratley RE, Denham DS, Trivedi R, et al.. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2026, 10.1038\/s41591-026-04440-4","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2026-116911","article-title":"LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial","volume":"16","author":"Alawadhi AA","year":"2026","unstructured":"Alawadhi AA, Alroudhan D, Alsaeed DJ, et al.. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. BMJ open. 2026, 16:e116911.","journal-title":"BMJ open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff AM","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023, 389:514-26. 10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock J","year":"2023","unstructured":"Rosenstock J, Frias JP, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023, 402:529-44. 10.1016\/S0140-6736(23)01053-X","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/511165-maximizing-metabolic-synergy-a-review-of-dual-incretin-therapy-as-a-step-up-strategy-following-glucagon-like-peptide-1-glp-1-monotherapy-failure-or-optimization","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:13:51Z","timestamp":1784106831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/511165-maximizing-metabolic-synergy-a-review-of-dual-incretin-therapy-as-a-step-up-strategy-following-glucagon-like-peptide-1-glp-1-monotherapy-failure-or-optimization"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.112694","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}